BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This advanced composite material features liposome-encapsulated hafnium-porphyrin quantum dots loaded with doxorubicin (DOX@Hf-TCPP@LIPs) designed with an inorganic-organic hybrid core-shell architecture. The complex internal structure encapsulates nanoscale hafnium-tetrakis(4-carboxyphenyl)porphyrin (Hf-TCPP) metal-organic framework quantum dots and hydrophilic doxorubicin (DOX) hydrochloride within the aqueous compartments of a robust phospholipid vesicle matrix. This design combines the distinct photodynamic and radiopotentiating characteristics of the porphyrinic quantum dots with the chemical release profile of an anthracycline drug. The surrounding lipid framework prevents quantum dot aggregation and controls the passive diffusion of the doxorubicin cargo.
Source
Custom synthesis
Functional Group
Quantum dots; Doxorubicin
Form
Solid or powder
Purity
≥95%
Impurities
No visible impurities to the naked eye.
Identity
HPLC/MS/NMR
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.